Figure 2.
Antiproliferative and pro-apoptotic effects of AGS-16C3F and cHmLYS-1c3.G2k-mcMMAF on human neoplastic mast cell lines. (A) ROSAKIT D816V-Gluc, HMC-1.1, and HMC-1.2 cells were treated with or without different concentrations of AGS-16C3F or cHmLYS-1c3.G2k-mcMMAF. On day 4 of treatment, viability was evaluated. Results are expressed as the percentage of control and represent the mean ± standard deviation of triplicates. (B) ROSAKIT D816V-Gluc, HMC-1.1, and HMC-1.2 cells were incubated in their medium (control) or with different concentrations of AGS-16C3F or cHmLYS-1c3.G2k-mcMMAF for 4 and 5 days. Results are expressed as the percentage of apoptotic cells, as measured by Annexin V/PI labeling.